Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 6 de 6
Filter
Add more filters










Database
Language
Publication year range
1.
Gynecol Oncol ; 181: 133-140, 2024 Feb.
Article in English | MEDLINE | ID: mdl-38163383

ABSTRACT

OBJECTIVE: We studied cis-women with uterine cancer presenting to the two Public Hospitals in Queens, New York from 2006 to 2015 to examine the relationship between nativity (birthplace) and survival. METHODS: A retrospective review of tumor registries identified women diagnosed with uterine cancer between January 1, 2006, and December 31, 2015. Data from 259 women were available for this analysis. RESULTS: Most women were born outside the United States (US) (76% versus 24%). The majority of US-born women were black (68%). Seventy-seven women (30%) were born in Latin America, 76 in the Caribbean Islands (29%) and 44 in Asia/South Asia (17%). Most women presented with stage I/II disease (70%) and endometrioid/mucinous histology (68%) with no significant differences observed among nativity groups. Kaplan-Meier estimated survival curves stratified by birthplace demonstrated significant differences in survival distributions among the groups using the log-rank test (P < 0.0001). The most favorable survival curves were observed among all foreign-born women, whereas the least favorable survival was demonstrated in US-born women. Time to death was analyzed using the Cox proportional hazards model. Adjusting for age of diagnosis, insurance status, stage, and treatment modality, Latin American and Asia/South Asia birthplace was significantly associated with increased survival time. CONCLUSION: An immigrant health paradox was defined for foreign-born Latin American and Asian/South Asian women presenting to the two Public Hospitals of Queens, New York, as women born in these geographic regions were less likely to die at any given time compared to those born in the United States.


Subject(s)
Emigrants and Immigrants , Uterine Neoplasms , Humans , Female , United States , New York/epidemiology , Retrospective Studies , Hospitals, Public
2.
Gynecol Oncol ; 149(1): 63-69, 2018 04.
Article in English | MEDLINE | ID: mdl-29605052

ABSTRACT

OBJECTIVE: We studied cervical cancer patients who presented to the Public Hospital System in ethnically-diverse Queens, New York from 2000 to 2010 with the purpose of examining the relationship between nativity (birthplace) and survival. METHODS: A retrospective review of tumor registries was used to identify patients diagnosed with cervical cancer between January 1, 2000 and December 31, 2010. Using electronic medical records, data from 317 patients were available for this analysis. RESULTS: The majority of patients were born outside the United States (US) (85.5% versus 14.5%). One hundred patients (31.5%) were born in Latin America, 105 in the Caribbean Islands (33.1%), 48 in Asia (15.1%), 8 in the South Asia (2.5%), 10 in Russia/Eastern Europe (3.2%) and 46 (14.5%) in the United States. Patients presented at varying stages of disease: 51.4% at stage I, 19.6% at stage II, 19.6% at stage III, and 8.5% at stage IV. Kaplan-Meier estimated survival curves stratified by birthplace demonstrated significant differences in survival distributions among the groups using the log-rank test (P<0.0001). The most favorable survival curves were observed among patients born in Latin America and Asia whereas the least favorable was demonstrated in US-born patients. Time to death was analyzed using the Cox proportional hazards model. Adjusting for age at diagnosis, insurance status, stage and treatment modality, nodal metastases and hydronephrosis, birthplace was significantly associated with survival time (P<0.0001). CONCLUSION: An immigrant health paradox was defined for foreign-born Latino and Asian patients presenting with cervical cancer to the Public Hospital System of Queens, New York as patients born in Latin America and Asia were less likely to die at any given time compared to those born in the United States.


Subject(s)
Uterine Cervical Neoplasms/ethnology , Uterine Cervical Neoplasms/mortality , Asia/ethnology , Emigrants and Immigrants/statistics & numerical data , Europe, Eastern/ethnology , Female , Health Status Disparities , Hospitals, Public/statistics & numerical data , Humans , Latin America/ethnology , Male , Middle Aged , New York City/epidemiology , Population Groups/statistics & numerical data , Proportional Hazards Models , Retrospective Studies , West Indies/ethnology
3.
Clin Respir J ; 11(6): 1086-1090, 2017 Nov.
Article in English | MEDLINE | ID: mdl-26646473

ABSTRACT

We report the first known case of malignant pleural effusion (MPE) as the sole presenting feature of clinically occult primary fallopian tube carcinoma (PFTC). A 57-year-old healthy woman was admitted with dyspnea. Evaluation demonstrated a right pleural effusion, fluid of which was malignant. The immunohistochemical profile, including negative calretinin, favored metastatic adenocarcinoma over mesothelioma but could not identify the primary tumour site. Pleural biopsy was not pursued as it would not have helped localize the primary. Chest, abdomen and pelvic computed tomography (CT) demonstrated only borderline lymphadenopathy in the left para-aortic lymph node chain that was hypermetabolic on positron emission tomography. Ultrasound and CT showed normal adnexal anatomy. These findings, coupled with an elevated serum CA-125, prompted empiric neoadjuvant chemotherapy targeting epithelial ovarian carcinoma (EOC) followed by surgery, which revealed a tiny left PFTC with negative peritoneal washings. Sampled left para-aortic lymph nodes were positive. The pleural effusion resolved after chemotherapy. Malignant pleural disease without peritoneal involvement is more characteristic of PFTC than of EOC, in which MPE is common but almost always accompanies peritoneal carcinomatosis. The extensive lymphatic supply of the fallopian tube promotes distant metastasis of small, seemingly localized tumours. This case is a reminder that the clinician should not be dissuaded from considering carcinoma of Müllerian origin, especially PFTC, as the cause of a MPE even in the face of normal gynecologic imaging. Appropriately broad immunohistochemical staining and careful attention to even minimal lymphadenopathy can be invaluable in pinpointing the primary tumour site in such patients.


Subject(s)
Carcinoma/pathology , Fallopian Tube Neoplasms/pathology , Fallopian Tubes/pathology , Lung Neoplasms/pathology , Mesothelioma/pathology , Pleural Effusion, Malignant/pathology , Carcinoma/drug therapy , Carcinoma/surgery , Carcinoma, Ovarian Epithelial , Chemotherapy, Adjuvant/methods , Dyspnea/diagnosis , Dyspnea/etiology , Female , Humans , Immunohistochemistry/methods , Lung Neoplasms/metabolism , Lung Neoplasms/secondary , Lymphatic Metastasis/pathology , Mesothelioma/metabolism , Mesothelioma/secondary , Mesothelioma, Malignant , Middle Aged , Neoplasms, Glandular and Epithelial/drug therapy , Neoplasms, Glandular and Epithelial/metabolism , Neoplasms, Glandular and Epithelial/pathology , Neoplasms, Glandular and Epithelial/surgery , Ovarian Neoplasms/drug therapy , Ovarian Neoplasms/metabolism , Ovarian Neoplasms/pathology , Ovarian Neoplasms/surgery , Pleura/pathology , Pleural Effusion, Malignant/drug therapy , Pleural Effusion, Malignant/etiology , Pleural Effusion, Malignant/surgery , Positron-Emission Tomography/methods , Thoracentesis/methods , Tomography, X-Ray Computed/methods
4.
J Reprod Med ; 53(7): 487-92, 2008 Jul.
Article in English | MEDLINE | ID: mdl-18720923

ABSTRACT

OBJECTIVE: To evaluate the clinical experience and outcomes of patients with gestational trophoblastic neoplasia (GTN) complicated by vaginal metastases. STUDY DESIGN: A review of patients with vaginal metastases from GTN treated at a regional trophoblastic disease center from 1962 to 2006. RESULTS: Vaginal metastases were present in 36 (4.5%) of the 804 patients treated for GTN. FIGO stage was II in 13 patients (36%), III in 22 patients (61%) and IV in 1 patient (3%). Twenty-three patients (65%) were low-risk by modified WHO criteria. The vaginal metastases were most frequently single lesions (61%) on the anterior vaginal wall (49%) with a histologic classification of choriocarcinoma (67%). Significant bleeding necessitated blood transfusion (median, 7 units; range, 1-26 units) in 13 patients (36%). Seven patients (19%) required 1 or more procedures for control of bleeding, including excision, suturing and/or hypogastric artery ligation/embolization. Twenty-three patients (64%) received single-agent chemotherapy with methotrexate and/or actinomycin-D, while 13 patients (36%) received multiagent chemotherapy regimens. CONCLUSION: Overall, 29 (81%) of 36 patients with vaginal metastases were cured. Vaginal metastasis from GTN does not uniformly confer a worse prognosis or necessitate multiagent chemotherapy, although procedures for control of bleeding may be required.


Subject(s)
Gestational Trophoblastic Disease/pathology , Gestational Trophoblastic Disease/therapy , Vaginal Neoplasms/therapy , Adolescent , Adult , Antineoplastic Agents/therapeutic use , Combined Modality Therapy , Female , Gynecologic Surgical Procedures , Humans , Middle Aged , Pregnancy , Retrospective Studies , Vaginal Neoplasms/secondary
6.
Arch Pathol Lab Med ; 129(5): 651-4, 2005 May.
Article in English | MEDLINE | ID: mdl-15859637

ABSTRACT

CONTEXT: Enhanced expression of GLUT1, a facilitative glucose transporter found on red blood cells, blood-brain barrier, and perineurium, has been described in a large spectrum of epithelial malignancies. OBJECTIVE: We present an immunohistochemical survey of GLUT1 expression in benign and malignant fallopian tube epithelia, and compare serous carcinomas of the fallopian tube and ovary. DESIGN: One hundred two routinely fixed and processed archival specimens (36 benign fallopian tubes, 29 primary tubal adenocarcinomas, and 37 primary ovarian adenocarcinomas) were immunostained with rabbit anti-GLUT1 and developed with streptavidin-biotin/diaminobenzidine. Only distinct membrane staining was scored positively (1+ to 3+). RESULTS: Benign tubes (n = 36) were either negatively stained (58.3%) or displayed rare weak staining (0.5+ to 1+, rarely 2+; 41.7%); of the latter, 4 specimens showed chronic salpingitis, and 6 showed hyperplasia (epithelial tufting and stratification). A case of florid hyperplasia with atypia in a BRCA1-positive patient was GLUT1 negative. Twenty-three (79.3%) of 29 tubal carcinomas were positively stained. Staining ranged from focal/scattered foci (n = 15) to multifocal/extensive (n = 8). Of the 6 nonstaining tubal carcinomas, 3 were undifferentiated. Nineteen tubal carcinoma sections showed residual benign epithelium, which was consistently nonstaining. Very frequently, GLUT1 staining intensified in cells furthest from stroma/ stromal capillaries and/or bordering necrotic zones. On average, GLUT1 staining in primary fallopian tube cancers was less extensive than in primary ovarian adenocarcinomas. CONCLUSIONS: GLUT1 immunostaining of fallopian tube adenocarcinomas was substantially stronger and more extensive than staining of benign tubal epithelium, consistent with previously described findings in carcinomas versus benign tissues from many primary sites. The frequent localization of GLUT1 positivity to regions most distal from stroma/stromal capillaries is consistent with known activation of GLUT1 expression by hypoxia-sensing cellular pathways and may constitute a survival advantage under hypoxic conditions present in malignancy. The difference in extent of GLUT1 staining between primary tubal and primary ovarian serous adenocarcinomas is discussed.


Subject(s)
Adenocarcinoma/metabolism , Fallopian Tube Neoplasms/metabolism , Fallopian Tubes/metabolism , Immunohistochemistry/methods , Monosaccharide Transport Proteins/metabolism , Ovarian Neoplasms/metabolism , Adenocarcinoma/pathology , Epithelial Cells/metabolism , Epithelial Cells/pathology , Fallopian Tube Neoplasms/pathology , Fallopian Tubes/anatomy & histology , Female , Glucose Transporter Type 1 , Humans , Hyperplasia/metabolism , Hyperplasia/pathology , Neoplasm Staging , Ovarian Neoplasms/pathology , Precancerous Conditions/metabolism , Precancerous Conditions/pathology
SELECTION OF CITATIONS
SEARCH DETAIL
...